Please assess the completion status of the following clinical trial:

Trial Title: Valproate in Late Life Schizophrenia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must have a diagnosis of schizophrenia as confirmed by the MINI~* Must be on antipsychotic medication~* Must be age 50 year or older~* Must be capable of providing written informed consent for study participation. In situations where individuals have guardians of person, guardian and subject must both provide written consent; and~* Must live in the Northeast Ohio area.~Exclusion Criteria:~* A primary psychiatric DSM Axis I diagnosis other than schizophrenia~* Actively abusing substances; or~* Medically unstable.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- valproate (Type: EXPERIMENTAL): All participants received open-label, add-on valproate.

Based on this trial design, predict the completion outcome and termination type (if applicable).